Skip to Content

GI Cancer Clinical Trials


NRG-GI004: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy  with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (DMMR) Metastatic Colorectal Cancer
Aims: The purpose of this study is to compare any good and bad effects of using chemotherapy alone compared to chemotherapy and an investigational new drug, Atezolizumab.
Diagnosis: Colorectal Cancer
Principal Investigator:
 Robert Marsh, MD
IRB Approval Number: EH18-189
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment:
Yes

 A021501: Preoperative Extended Chemotherapy Versus Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Aims: The purpose of this study is to compare any good and bad effects of using chemotherapy alone compared to chemotherapy and radiation prior to surgery.
Diagnosis: Pancreas
Principal Investigator:
 Robert Marsh, MD
IRB Approval Number: EH17-183
Sponsor: Alliance in Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment:
suspended

CG001: Evaluation of the Performance of the Clinical Genomics Colvera Test in the Detection of Disease Recurrence in Patients with Diagnosed Colorectal Cancer (NOVA)
Aims: The purpose of this study is to test a new way of detecting the recurrence of colon cancer after patients have received initial treatment.
Diagnosis: Colorectal Cancer
Principal Investigator: Marisa Hill, MD
IRB Approval Number: EH18-195
Sponsor: Clinical Genomics
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

The Pancreatic Sample Repository
Aims: Collect blood, pancreatic secretions and pancreatic tissue from patients undergoing surgery for pancreatic diseases, including cancer and store these samples in a repository for future studies done at NorthShore or at collaborating institutions
Diagnosis: Any pancreatic disease
Principal Investigator: Karen Kaul, MD 
IRB Approval Number: EH02-186
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact Susan Jane Stocker, LPN, BLS, CCRP at 847.570.1322, sstocker@northshore.org or Gnathan Carpenter, RN at 847.570.2949, gcarpenter@northshore.org
Open to Enrollment: Yes

Clinical Pancreatic Cancer Database
Aims: Capture, review, and compare medical information, including symptoms, treatments, and complications that people with pancreatic diseases have and store this information for future research studies done at NorthShore or with collaborating institutions.
Diagnosis: Any pancreatic disease
Principal Investigator: Mark S. Talamonti, MD
IRB Approval Number: EH08-197T
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact Susan Jane Stocker, LPN, BLS, CCRP at 847.570.1322, sstocker@northshore.org or Gnathan Carpenter, RN at 847.570.2949, gcarpenter@northshore.org
Open to Enrollment: Yes

Boston Biomedical: CanStem 303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)
Aims: 
The purpose of this study
Diagnosis: Colorectal Cancer
Principal Investigator: Marisa Hill, MD
IRB Approval Number: EH17-219
Sponsor: Boston Biomedical
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698

EA2165: Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High-Risk Anal Cancer

Aims: The purpose of this study
Diagnosis: 
Principal Investigator: Marisa Hill, MD
IRB Approval Number: EH19-071
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes